Akiram Therapeutics
advancing radio-therapeutics to treat solid tumors
Science-driven Development of Cancer Targeting Radiopharmaceuticals
Akiram Therapeutics pioneers targeted radioimmunotherapy for solid cancers, using innovative radioactive molecules for precise diagnosis and treatment. Discover more about our groundbreaking approach that has shown promising results in preclinical studies.
About Akiram Therapeutics: Leaders in Radioimmunotherapy
We are dedicated to revolutionizing cancer treatment through cutting-edge radioimmunotherapy. With roots in Uppsala University’s pioneering research, our focus is on delivering targeted radioactivity to cancer cells while preserving healthy tissues. Our mission is to bring new, effective treatments to patients with limited options.
Explore our story, meet our expert team, and learn about our innovative approach to transforming cancer care.
Experts in Radiation Sciences
The Akiram team has extensive expertise in radiation sciences, cancer precision medicine, and drug discovery and development. Our team includes specialists in production (CMC), oncologists, and hospital physicists, all crucial for advancing our clinical development efforts.
Invest in the Future of Cancer Treatment
Akiram Therapeutics leads a transformative approach to challenging cancers. Focusing on metastatic solid cancer, we offer targeted radioimmunotherapy with unprecedented preclinical success. Our pioneering treatment provides hope for a first-in-class therapy. Join us to advance this groundbreaking therapy and transform lives. Partner with us as we move into clinical trials and beyond.Latest News from Akiram Therapeutics
